Pro-Neurogenic Compounds
    3.
    发明申请
    Pro-Neurogenic Compounds 有权
    前神经源性化合物

    公开(公告)号:US20140057900A1

    公开(公告)日:2014-02-27

    申请号:US13974642

    申请日:2013-08-23

    摘要: Compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.

    摘要翻译: 本文公开了用于刺激神经发生(例如,产后神经发生,包括产后海马和下丘脑神经发生)和/或保护神经细胞免于细胞死亡的化合物和方法。 体内活性测试表明,这些化合物可能在神经精神和/或神经变性疾病如精神分裂症,主要抑郁症,双相性精神障碍,正常衰老,癫痫,创伤性脑损伤,创伤后应激障碍,帕金森病,阿尔茨海默病, 唐氏综合征,脊髓小脑性共济失调,肌萎缩性侧索硬化,亨廷顿病,中风,放射治疗,慢性应激,神经活性药物滥用,视网膜变性,脊髓损伤,周围神经损伤,与各种病症相关的生理体重减轻 作为与正常老化,化学疗法等相关的认知衰退。

    Method for preparing opipramol
    4.
    发明授权
    Method for preparing opipramol 失效
    制备opipramol的方法

    公开(公告)号:US5599929A

    公开(公告)日:1997-02-04

    申请号:US336837

    申请日:1994-11-09

    CPC分类号: C07D223/26 C07D223/22

    摘要: An improved method for preparing opipramol (I) is disclosed, wherein iminostilbene (II) is reacted with 1-bromo-3-chloropropane in the presence of a weak base selected from a hydrogen phosphate salt and an acetate salt and in the presence of a phase transfer agent to produce N-(3-halopropyl)iminostilbene (III), which is mixture of N-(3-chloropropyl)iminostilbene and N-(3-bromopropyl)iminostilbene, and then N-(3-halopropyl)iminostilbene is reacted with N-(2-hydroxyethyl)piperazine to form opipramol, as shown in the following equations, where X is chlorine or bromine. ##STR1##

    摘要翻译: 公开了一种制备奥美拉莫(I)的改进方法,其中亚氨基茋(II)在1-碱金属络合物的存在下,在选自磷酸氢盐和乙酸盐的弱碱的存在下,与1-溴-3-氯丙烷反应, 相转移剂生产N-(3-氯丙基)亚氨基芪和N-(3-溴丙基)亚氨基芪的混合物N-(3-卤代丙基)亚氨基芪(III),然后N-(3-卤代丙基)亚氨基芪 与N-(2-羟乙基)哌嗪反应以形成吡哆醇,如下式所示,其中X为氯或溴。 +图像

    Fluoresence polarization immunoassay
    5.
    发明授权
    Fluoresence polarization immunoassay 失效
    荧光极化免疫测定

    公开(公告)号:US5391740A

    公开(公告)日:1995-02-21

    申请号:US044927

    申请日:1993-04-08

    摘要: This disclosure relates to a method and reagents for determining ligands in biological fluids such as serum, plasma, spinal fluid, amnionic fluid and urine. In particular, this disclosure relates to a fluorescence polarization immunoassay procedure and to a novel class of tracer compounds employed as reagents in such procedures. The procedure disclosed combines the specificity of an immunoassay with the speed and convenience of fluorescence polarization techniques to provide a means for determining the amount of the specific ligand present in a sample.

    摘要翻译: 本公开涉及用于测定生物流体如血清,血浆,脊髓液,羊膜液和尿液中配体的方法和试剂。 特别地,本发明涉及荧光偏振免疫测定方法以及在这种方法中用作试剂的新型示踪剂化合物。 所公开的方法将免疫测定的特异性与荧光偏振技术的速度和方便性相结合,以提供测定样品中存在的特异性配体的量的方法。

    5-Substituted derivatives of 5H-dibenz (b,f)-azepine and method for
obtaining the same
    9.
    发明授权
    5-Substituted derivatives of 5H-dibenz (b,f)-azepine and method for obtaining the same 失效
    5-取代的5H-二苯并(b,f) - 氮杂衍生物及其获得方法

    公开(公告)号:US4124583A

    公开(公告)日:1978-11-07

    申请号:US715792

    申请日:1976-08-19

    IPC分类号: C07D223/24 C07D223/22

    CPC分类号: C07D223/22

    摘要: The invention covers the following compounds: 5-(N-benzoylthiocarbamoyl)-5H-dibenz [b, f] azepine, 5-thiocarbamoyl-5H-dibenz [b,f] azepine, 5-(S-methylisothiocarbamoyl)-5H-dibenz [b,f]-azepine and their 10,11-dihydro analogs. These compounds are intermediates for psychoactive drugs.

    摘要翻译: 本发明涵盖以下化合物:5-(N-苯甲酰基硫代氨基甲酰基)-5H-二苯并[b,f]氮杂,5-硫代氨基甲酰基-5H-二苯并[b,f]氮杂,5-(S-甲基异硫代氨基甲酰基)-5H-二苯并 [b,f] - 氮杂及其10,11-二氢类似物。 这些化合物是精神药物的中间体。